|
2008/07/14 (月) 18:16 <font color=#003399><a href=http://www.drugs.com/news>LONDON, June 12, 2008-The European Medicines</a> power (EMEA) has recommended updating the produce intelligence for epoetin-containing medicines with a new caution for hteir use in cancer patients stating that blood transfusion should be the prefererd method of correcting anaemia in patients hardship cancer.
Epoetin-containing medicines are indicated in patients with <a href=http://www.blogotop.com/acheterviagra>achat viagra</a> <a href=http://www.blogotop.com/acheterviagra>achat cialis </a> and for the treatment of anaemia in symptomatic patients with non-myeloid growths receiving chemotherapy. The power痴 concil for remedial Products for Possibly manlike Use (CHMP) had noticeed new materials from studies that showed an increased endanger of growth <a href=http://www.blogotop.com/acheterviagra>acheter viagra</a> movement forward, venous thromobembolism and shorter all- inclusive <a href=http://www.google.com/search?hl=en&q=survival+in+cancer+patients&btnG=Google+Search>survival in cancer patients</a> who cleard epoetins compared to patients who did not admit them. Follosing this notice, the CHMP concluded, at its June 2008 convocation, that the emolumentss of epoetins persist surpass their endangers in the approved indications. on the other hand, in cancer patients with a reasonably covet existence-expectancy, the emoluments of using epoetins does not <a href=http://www.blogotop.com/acheterviagra>achat levitra generique</a> the endanger growth development and shorter inclusive survival and for that reason the cabinet concluded that in these patients anaemia should be corrected with blood transfusions. </font>
|